Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ideal target for next generation of anti-inflammatory drugs without the side effects of currently available anti-inflammatory drugs. However, there has been no clinically promising mPGES-1 inhibitor identified through traditional drug discovery and development route. Here we report a new approach, called DREAM- in -CDM ( D rug R epurposing E ffort A pplying Integrated M odeling- in vitro/vivo – C linical D ata M ining), to identify an FDA-approved drug suitable for use as an effective analgesic targeting mPGES-1. The DREAM- in -CDM approach consists of three steps: computational screening of FDA-approved drugs; in vitro and/or in vivo assays; and clinical data mining. By using the DREAM- in -CDM approach, lapatinib has been identified as a promising mPGES-1 inhibitor which may have significant anti-inflammatory effects to relieve various forms of pain and possibly treat various inflammation conditions involved in other inflammation-related diseases such as the lung inflammation caused by the newly identified COVID-19. We anticipate that the DREAM- in -CDM approach will be used to repurpose FDA-approved drugs for various new therapeutic indications associated with new targets.
【저자키워드】 Virtual drug screening, Screening, 【초록키워드】 COVID-19, Inflammation, Anti-inflammatory drugs, Drug discovery, in vitro, Pain, targets, in vivo, inhibitor, disease, Lung inflammation, Side effect, Clinical data, FDA-approved drug, treat, anti-inflammatory drug, anti-inflammatory effect, approach, effective, identify, caused, involved, clinically, form, condition, therapeutic indication, 【제목키워드】 drug, identification, targeting, Generation, New,